Sangamon Sun

In a significant move to combat the rising threat of certain synthetic drugs in Illinois, the state's Senate has approved legislation aimed at more strictly regulating xylazine, often referred to as the "zombie drug." The bill, Senate Bill 1773, is co-sponsored by State Senator Sally Turner (R-Beason).

Senate Bill 1773 proposes amendments to the Illinois Controlled Substances Act, reclassifying xylazine as a Schedule III controlled substance. This comes in response to an increase in overdose cases linked to the drug. The bill not only intensifies penalties for the illegal handling of xylazine but also maintains necessary safeguards for its legitimate use in veterinary and wildlife settings.

"We are seeing a rise in dangerous substances like xylazine being mixed with fentanyl and other illicit drugs, often without the user even knowing," said Senator Sally Turner. "This legislation ensures Illinois law keeps pace with this growing threat and gives law enforcement and public health officials the tools they need to respond."

Recent data from the Illinois Department of Public Health indicates that xylazine was involved in 45 overdose deaths in 2020, a number that climbed to over 200 by 2022. Though xylazine is not sanctioned for human use, it is frequently used to amplify the effects of other substances, resulting in increased risks and treatment challenges.

"This is exactly the kind of emerging threat that lawmakers need to take seriously," Senator Turner continued. "We cannot wait until more lives are lost before we act. This bill is about being proactive, protecting our communities, and giving law enforcement the tools they need to respond."

The support from Senator Turner for Senate Bill 1773 is part of her ongoing commitment to enhancing the state's response to synthetic drugs and the opioid crisis. The legislation is now set to proceed to the House for further review.